PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
J D Jensen, Ann Knoop, A V Laenkholm, M Grauslund, M B Jensen, E Santoni-Rugiu, M Andersson, Marianne Ewertz, M B Jensen
106Citations
(Scopus)
Fingerprint
Dive into the research topics of 'PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab'. Together they form a unique fingerprint.